Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.
Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.
复制标题
通过将 HPβCD 封装在聚合物纳米颗粒中,提高非瑟酮的口服生物利用度和抗癌功效。
DOI:
10.1080/10717544.2016.1245366
复制
发表时间:
2017-11
期刊:
影响因子:
6
通讯作者:
Sistla R
中科院分区:
文献类型:
--
作者:
Kadari A;Gudem S;Kulhari H;Bhandi MM;Borkar RM;Kolapalli VR;Sistla R
Fisetin (FST), a potent anticancer phytoconstituent, exhibits poor aqueous solubility and hence poor bioavailability. The aim of the present study is to improve the oral bioavailability of FST by encapsulating into PLGA NPs (poly-lactide-co-glycolic acid nanoparticles) as a complex of HPβCD (hydroxyl propyl beta cyclodextrin) and to assess its anti-cancer activity against breast cancer cells. FST-HPβCD inclusion complex (FHIC) was prepared and the supramolecular complex formation was characterized by FTIR, DSC, PXRD and 1H NMR. FHIC encapsulated PLGA nanoparticles (FHIC-PNP) were prepared and were studied for in vitro anticancer activity, cellular uptake, apoptosis and reactive oxygen species generation in MCF-7 human breast cancer cells. Comparative bioavailability of FST was determined after oral administration in C57BL6 mice as pure FST and FHIC-PNP. The results revealed that FHIC-PNP not only enhanced the anti-cancer activity and apoptosis of FST against MCF-7 cells but also improved its oral bioavailability, as demonstrated by increased peak plasma concentration and total drug absorbed.
登录
查看更多内容
影响因子:
--
作者:
Maurya BK;Trigun SK
通讯作者:
Trigun SK
影响因子:
11.2
作者:
Hu, Liandong;Zhang, Hailei;Hu, Qiaofeng
通讯作者:
Hu, Qiaofeng
影响因子:
6.6
作者:
Bothiraja, Chellampillai;Yojana, Bhagwat D.;Thorat, Uday H.
通讯作者:
Thorat, Uday H.
影响因子:
9.7
作者:
Jang, Ki Young;Jeong, Soo-Jin;Kim, Sung-Hoon
通讯作者:
Kim, Sung-Hoon
DOI:
10.1016/j.ijbiomac.2014.05.035
发表时间:
2014-08-01
影响因子:
8.2
作者:
Pooja, Deep;Bikkina, Dileep J. Babu;Tiwari, Ashok K.
通讯作者:
Tiwari, Ashok K.